

## Pragmatica-Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer

**Status:** Recruiting

### Eligibility Criteria

**Sex:** Male or Female

**Age Group:** 18 years and over

This study is NOT accepting healthy volunteers

**Inclusion Criteria:**

- at least 18 years old - confirmed non-small cell lung cancer (NSCLC) which is stage IV (metastatic) or has recurred - must have received at least one previous treatment of immune therapy - must have received platinum-based chemotherapy - able to care for self with occasional assistance

---

**Exclusion Criteria:**

- may not have received more than one treatment with immunotherapy for stage IV or recurrent disease - may not receive receive another investigational drug during study participation

### Conditions & Interventions

**Interventions:**

Drug: Chemotherapy, Biological: Pembrolizumab, Biological: Ramucirumab

**Conditions:**

Cancer

**Keywords:**

Immunotherapy, Lung Cancer, Lung Cancer, Non Small cell lung cancer, NSCLC, Stage IV lung cancer

### More Information

**Description:** We are comparing the effectiveness of the combination of ramucirumab and pembrolizumab compared to the usual chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). The drugs work in different ways to stop the growth of tumor cells. We will compare how well the treatment regimens work and the side effects that occur.

**Study Contact:** Kristen Nelson - knelso65@fairview.org

**Principal Investigator:** Nicole Hartung

**IRB**

**Number:** MMCORC068

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.